Klaria Pharma Holding AB (publ.) (KLAR.ST)

SEK 0.29

(-8.63%)

Total Liabilities Summary of Klaria Pharma Holding AB (publ.)

Klaria Pharma Holding AB (publ.)'s latest annual total liabilities in 2023 was 31.98 Million SEK , down -27.62% from previous year.
Klaria Pharma Holding AB (publ.)'s latest quarterly total liabilities in 2024 Q1 was 39.79 Million SEK , up 24.41% from previous quarter.
Klaria Pharma Holding AB (publ.) reported annual total liabilities of 44.19 Million SEK in 2022, down -9.62% from previous year.
Klaria Pharma Holding AB (publ.) reported annual total liabilities of 48.89 Million SEK in 2021, up 114.33% from previous year.
Klaria Pharma Holding AB (publ.) reported quarterly total liabilities of 44.97 Million SEK for 2024 Q2, up 13.02% from previous quarter.
Klaria Pharma Holding AB (publ.) reported quarterly total liabilities of 24.76 Million SEK for 2023 Q1, down -43.97% from previous quarter.

Annual Total Liabilities Chart of Klaria Pharma Holding AB (publ.) (2023 - 2014)

Historical Annual Total Liabilities of Klaria Pharma Holding AB (publ.) (2023 - 2014)

Year	Total Liabilities	Total Liabilities Growth
2023	31.98 Million SEK	-27.62%
2022	44.19 Million SEK	-9.62%
2021	48.89 Million SEK	114.33%
2020	22.81 Million SEK	16.29%
2019	19.61 Million SEK	69.77%
2018	11.55 Million SEK	391.91%
2017	2.34 Million SEK	17.8%
2016	1.99 Million SEK	-13.04%
2015	2.29 Million SEK	356.14%
2014	502.69 Thousand SEK	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q1	39.79 Million SEK	24.41%
2024 Q2	44.97 Million SEK	13.02%
2023 Q1	24.76 Million SEK	-43.97%
2023 Q2	24.75 Million SEK	-0.02%
2023 Q3	25.32 Million SEK	2.32%
2023 Q4	31.98 Million SEK	26.28%
2023 FY	31.98 Million SEK	-27.62%
2022 Q3	52.1 Million SEK	18.24%
2022 FY	44.19 Million SEK	-9.62%
2022 Q2	44.06 Million SEK	-2.86%
2022 Q1	45.36 Million SEK	-7.22%
2022 Q4	44.19 Million SEK	-15.19%
2021 Q3	23.97 Million SEK	-6.78%
2021 Q2	25.71 Million SEK	-52.07%
2021 FY	48.89 Million SEK	114.33%
2021 Q1	53.66 Million SEK	135.25%
2021 Q4	48.89 Million SEK	103.95%
2020 Q2	21.82 Million SEK	-22.68%
2020 FY	22.81 Million SEK	16.29%
2020 Q4	22.81 Million SEK	13.6%
2020 Q1	28.23 Million SEK	43.91%
2020 Q3	20.08 Million SEK	-8.0%
2019 Q3	22.69 Million SEK	-4.08%
2019 Q2	23.66 Million SEK	87.96%
2019 Q1	12.59 Million SEK	8.96%
2019 FY	19.61 Million SEK	69.77%
2019 Q4	19.61 Million SEK	-13.58%
2018 Q1	2.86 Million SEK	22.01%
2018 Q3	2.36 Million SEK	12.45%
2018 FY	11.55 Million SEK	391.91%
2018 Q4	11.55 Million SEK	388.17%
2018 Q2	2.1 Million SEK	-26.55%
2017 Q2	2.15 Million SEK	-20.98%
2017 FY	2.34 Million SEK	17.8%
2017 Q1	2.72 Million SEK	36.46%
2017 Q4	2.34 Million SEK	25.28%
2017 Q3	1.87 Million SEK	-12.79%
2016 Q4	1.99 Million SEK	18.48%
2016 FY	1.99 Million SEK	-13.04%
2016 Q3	1.68 Million SEK	-29.9%
2016 Q2	2.4 Million SEK	-16.78%
2016 Q1	2.88 Million SEK	25.82%
2015 FY	2.29 Million SEK	356.14%
2015 Q3	711 Thousand SEK	0.0%
2015 Q4	2.29 Million SEK	222.5%
2014 FY	502.69 Thousand SEK	0.0%

Peer Total Liabilities Comparison of Klaria Pharma Holding AB (publ.)

Name	Total Liabilities	Total Liabilities Difference
AcuCort AB	10.97 Million SEK	-191.444%
AlzeCure Pharma AB (publ)	8.22 Million SEK	-288.793%
BioGaia AB (publ)	302.84 Million SEK	89.438%
Enzymatica AB (publ)	49.3 Million SEK	35.122%
Enorama Pharma AB (publ)	14.84 Million SEK	-115.437%
Gabather AB (publ)	6.87 Million SEK	-365.048%
Moberg Pharma AB (publ)	24 Million SEK	-33.236%
Nanexa AB (publ)	36.42 Million SEK	12.192%
Newbury Pharmaceuticals AB (publ)	38.95 Million SEK	17.888%
ODI Pharma AB	10.05 Million SEK	-218.026%
Orexo AB (publ)	727.7 Million SEK	95.605%
Probi AB (publ)	181.31 Million SEK	82.359%
Swedencare AB (publ)	2.31 Billion SEK	98.618%
Swedish Orphan Biovitrum AB (publ)	40.16 Billion SEK	99.92%
Toleranzia AB	6.9 Million SEK	-362.961%
Vivesto AB	30.45 Million SEK	-5.037%